Drug Research

Concert Pharmaceuticals asserted the next development candidate CTP-692, a novel drug for adjunctive treatment of schizophrenia, a devastating, chronic illness with significant unmet…
Read More...

U.S Food and Drug Administration ensures that patients and providers have timely and continued access to safe, effective, and high-quality medical products. FDA’s Center for Drug…
Read More...

MAIA Pharmaceuticals, NJ based specialty pharmaceutical company asserted tentative approval of Sincalide for Injection NDA by the U.S. Food and Drug Administration. As far as 2013 is…
Read More...

BioAtla which is a global biotechnology company aiming to develop Conditionally Active Biologic protein Therapeutics announced the treatment of first patient in its clinical trial…
Read More...

Sangamo Therapeutics declared that the Medicines and Healthcare Products Regulatory Agency of the United Kingdom has extended Clinical Trial Authorization for enlisting subjects into…
Read More...

MabVax Therapeutics , a clinical-stage biotechnology company that aims to develop antibody-based products to address unattainable medical needs to treat cancer declared positive results…
Read More...

Second Genome which is considered a leader in the development of novel medicines derived from the human microbiome initiated four collaborations with key academic institutions to assess…
Read More...

Spruce Biosciences which is a clinical-stage biotechnology company developing novel therapies for rare endocrine disorders asserted the launch of its Congenital Adrenal Hyperplasia…
Read More...

ENYO Pharma SA declared that it is strengthening its leadership team with the appointment of a VP Non-Clinical Development & Product Profiling. ENYO Pharma also confirms that its…
Read More...

ALung Technologies asserted that it has initiated enrolling patient in its VENT-AVOID Trial of the Hemolung RAS. The Minneapolis Heart Institute Foundation recently enrolled the first…
Read More...

Johnson and Johnson Medical Companies asserted that Acclarent,Inc which is a leader in developing minimally-invasive Ear, Nose and Throat technologies has sought clearance from the U.S…
Read More...

Houston-based company specializing in dental sleep medicine and sleep apnea treatment, The Center for Craniofacial & Dental Sleep Medicine (CFDSM) assured that it has sought FDA…
Read More...

Sierra Oncology which is a clinical stage drug development company aiming to further the DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer, today…
Read More...

Celltex Therapeutics Corporation asserted its authorization to conduct an investigational protocol which is a Phase II B Wellness Protocol Clinical Study on Rheumatoid Arthritis and…
Read More...

Aldeyra Therapeutics enters into a collaborative research agreement with Janssen Research and Development, LLC which is ideally one of the Janssen Pharmaceutical Companies of Johnson…
Read More...

Aridis Pharmaceuticals applying proprietary technologies to curate novel anti-infectives and immunotherapies for infectious diseases proclaimed that it has created a Joint Venture with …
Read More...

Amgen asserted that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion recommending a label variation for Neulasta…
Read More...

Abbott and Surmodics proclaimed having forayed into an agreement wherein Abbott will possess exclusive commercialization rights for Surmodic's Surveil drug-coated balloon to treat the…
Read More...

Longeveron asserted that its revolutionary Clinical Trial initiated to treat infants with Hypoplastic Left Heart Syndrome as the first patient received the treatment using the company's…
Read More...

Medical device company reinventing venous access using proprietary material technology designed to reduce thrombus accumulation, Access Vascular asserted that the Company has sought …
Read More...